Skip to main content

Table 4 Changes in the concomitant immunosuppressants use before and after the introduction of MPZ

From: Effectiveness and safety of mepolizumab in combination with corticosteroids in patients with eosinophilic granulomatosis with polyangiitis

Case No.

Pre-MPZ

Post-MPZ

− 12 months

− 11 months

− 9 months

− 6 months

0 months

1 months

3 months

6 months

12 months

1

MTX 8 mg

MTX 8 mg

None

None

None

None

None

None

None

2

MTX 8 mg+AZ 125 mg

MTX 8 mg+AZ 125 mg

MTX 8 mg+AZ 125 mg

MTX 8 mg+AZ 125 mg

MTX 8 mg+AZ 125 mg

AZ125 mg

AZ125 mg

AZ125 mg

AZ100 mg

3

AZ50 mg

AZ50 mg

AZ 50 mg

AZ 50 mg

AZ 50 mg

AZ 50 mg

AZ 50 mg

AZ 50 mg

AZ 50 mg

4

None

None

AZ 50 mg

None

None

None

None

MTX 8 mg

MTX 8 mg

5

MTX 6 mg+AZ 50 mg

MTX 6 mg+AZ 50 mg

MTX 6 mg+AZ 50 mg

MTX 6 mg+AZ 50 mg

MTX 6 mg+AZ 50 mg

AZ 50 mg

AZ 50 mg

AZ 50 mg

AZ 50 mg

6

MTX 16 mg

MTX 16 mg

MTX 16 mg

MTX 16 mg

MTX 16 mg

MTX 16 mg

MTX 10 mg

MTX 4 mg

None

7

None

None

None

None

None

None

None

None

None

8

MTX 12 mg

MTX 12 mg

MTX 12 mg

MTX 12 mg

MTX 12 mg

None

None

None

None

9

AZ 50 mg

AZ 50 mg

AZ 50 mg

AZ 50 mg

AZ 50 mg

None

None

None

None

10

None

None

IVCY

None

None

None

None

None

None

11

TAC 3 mg

TAC 3 mg

TAC 3 mg

TAC 3 mg

TAC 3 mg

None

None

None

None

12

None

None

None

None

None

None

None

None

None

13

AZ 50 mg

AZ 50 mg

AZ 50 mg

AZ 50 mg

AZ 50 mg

AZ 50 mg

AZ 50 mg

AZ 50 mg

AZ 50 mg

14

None

None

None

None

None

None

None

None

None

15

AZ 100 mg

AZ 100 mg

AZ 100 mg

AZ 100 mg

AZ 100 mg

None

None

None

None

16

None

None

None

None

None

None

None

None

None

  1. IVCY cyclophosphamide pulse therapy i.v., MTX methotrexate, AZ azathioprine, TAC tacrolimus